

1. Sales January to September 2003 and 2002

January – September	2003	2002	% change	
	CHF m	CHF m	In CHF	In local currencies
Pharmaceuticals ^{1, 2}	15,767	13,903	13%	23%
Roche Prescription ^{1, 3}	9,792	9,705	1%	7%
Genentech Prescription	2,515	2,380	6%	24%
Chugai Prescription ^{2, 4}	2,142	671	219%	250%
Prescription ^{1, 2}	14,449	12,756	13%	23%
OTC ^{2, 5}	1,318	1,147	15%	21%
Diagnostics	5,418	5,367	1%	7%
Group core businesses ^{1, 2}	21,185	19,270	10%	19%
Vitamins and Fine Chemicals	2,263	2,574	-12%	-5%
Reclassification ¹	-96	-143		
Group (financial statements)	23,352	21,701	8%	16%

¹ Sales in 2003 and 2002 are adjusted to include the reclassification of CHF 96 m and CHF 143 m of sales to the Vitamins and Fine Chemicals Division as divisional sales to third parties

² Chugai is consolidated as from 1 October 2002

³ Excludes Nippon Roche Rx

⁴ Consists of Nippon Roche Rx (First 9 months in 2002) and Chugai Rx (First 9 months in 2003)

⁵ Consists of Roche OTC and Chugai OTC

2. Quarterly local sales growth by Division in 2002 and 2003

	Q4 2002 vs. Q4 2001	Q1 2003 vs. Q1 2002	Q2 2003 vs. Q2 2002	Q3 2003 vs. Q3 2002
Pharmaceuticals¹	18%	18%	24%	28%
Roche Prescription ^{1,2}	-1%	3%	8%	13%
Genentech Prescription	23%	25%	24%	22%
Chugai Prescription ³	211%	236%	242%	274%
Prescription ¹	18%	18%	24%	28%
OTC ⁴	9%	13%	23%	27%
Diagnostics	10%	7%	7%	7%
Group core businesses¹	16%	15%	19%	22%
Vitamins and Fine Chemicals	5%	-3%	-4%	-7%
Group (financial statements)	14%	13%	17%	19%

¹ Sales are adjusted to include the reclassification of sales to the Vitamins and Fine Chemicals Division as divisional sales to third parties

² Excludes Nippon Roche Rx

³ Consists of Nippon Roche Rx (until 30 September 2002) and Chugai Rx (from October 2002)

⁴ Consists of Roche OTC and Chugai OTC

3. Core Division's quarterly sales in 2002 and 2003

CHF millions	Q4 2002	Q1 2003	Q2 2003	Q3 2003
Pharmaceuticals¹	5,403	4,991	5,320	5,456
Roche Prescription ¹	3,171	3,136	3,273	3,383
Genentech Prescription	871	793	830	892
Chugai Prescription	915	656	755	731
Prescription ¹	4,957	4,585	4,858	5,006
OTC ²	446	406	462	450
Diagnostics	1,872	1,738	1,831	1,849
Group core businesses¹	7,275	6,729	7,151	7,305

¹ Sales are adjusted to include the reclassification of sales to the Vitamins and Fine Chemicals Division as divisional sales to third parties

² Consists of Roche OTC and Chugai OTC

4. Top 20 prescription medicines sales^{1,2} and local growth³ in the first 9 months of 2003, US, Japan and Europe/Rest of World

	Total		US		Japan		Europe/RoW	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	2,023	36%	1428	32%	58	30%	537	51%
Neo Recormon/Epogin	1,509	128%	-	-	572	-	937	37%
Rocephin	1,023	-7%	591	-5%	38	12%	394	-12%
Cellcept	989	28%	508	26%	14	21%	467	30%
Herceptin	871	31%	415	20%	67	53%	389	41%
Pegasys/Copegus	619	1483%	387	-	-	-	232	445%
Xenical	471	-13%	113	-15%	-	-	358	-13%
Xeloda	409	36%	220	31%	5	-	184	41%
Roaccutan/Accutane	406	-40%	227	-48%	-	-	179	-24%
Nutropin/Protopin	335	8%	326	8%	-	-	9	11%
Kytril	321	8%	137	4%	93	11%	91	11%
Dilatrend	286	19%	-	-	-	-	286	19%
Pulmozyme	243	11%	143	11%	-	-	100	11%
Neutrogen	234	-	-	-	234	-	-	-
Activase/TNKase	215	8%	192	8%	-	-	23	7%
Cymevene/Valcyte	214	6%	130	2%	-	-	84	14%
Viracept	211	-13%	-	-	2	-5%	209	-13%
Madopar	179	4%	-	-	13	-1%	166	5%
Lexotan	161	-8%	-	-	9	-3%	152	-9%
Inhibace/Inhibace Plus	159	-1%	-	-	8	-28%	151	1%
Fuzeon	25	-	20	-	-	-	5	-

¹ Roche Rx, Genentech Rx and Chugai Rx combined

² Chugai is consolidated as from 1 October 2002

³ versus Q3 in 2002

5. Top 20 prescription medicines quarterly local sales growth^{1,2} in 2002 and 2003

	Q4 2002 vs. Q4 2001	Q1 2003 vs. Q1 2002	Q2 2003 vs. Q2 2002	Q3 2003 vs. Q3 2002
MabThera/Rituxan	42%	39%	37%	32%
NeoRecormon/Epogin	165%	120%	139%	124%
Rocephin	-15%	-16%	-3%	4%
Cellcept	26%	39%	19%	28%
Herceptin	24%	36%	32%	26%
Pegasys/Copegus	581%	2226%	1458%	1283%
Xenical	-12%	-19%	-11%	-11%
Xeloda	61%	50%	52%	11%
Roaccutan/Accutane	-44%	-34%	-48%	-39%
Nutropin/Protropin	19%	13%	8%	4%
Kytril	40%	-7%	17%	13%
Dilatrend	17%	16%	22%	18%
Pulmozyme	2%	10%	15%	6%
Neutrogen	-	-	-	-
Activase/TNKase	16%	11%	10%	2%
Cymevene/Valcyte	14%	-10%	1%	37%
Viracept	-38%	-18%	11%	-27%
Madopar	2%	6%	1%	6%
Lexotan	-4%	-11%	-11%	-3%
Inhibace/Inhibace Plus	1%	7%	-13%	3%

¹ Roche Rx, Genentech Rx and Chugai Rx combined

² Chugai is consolidated as from 1 October 2002

6. Prescription medicines quarterly local sales growth¹ US in 2002 and 2003

	Q4 2002 vs. Q4 2001	Q1 2003 vs. Q1 2002	Q2 2003 vs. Q2 2002	Q3 2003 vs. Q3 2002
MabThera/Rituxan	38%	33%	33%	30%
NeoRecormon/Epogin	-	-	-	-
Rocephin	-19%	-20%	5%	11%
Cellcept	40%	49%	8%	27%
Herceptin	2%	21%	20%	20%
Pegasys/Copegus	-	-	-	-
Xenical	-8%	-24%	1%	-22%
Xeloda	64%	51%	60%	-14%
Roaccutan/Accutane	-55%	-37%	-57%	-52%
Nutropin/Protropin	19%	13%	8%	4%
Kytril	103%	-23%	24%	14%
Dilatrend	-	-	-	-
Pulmozyme	7%	17%	13%	3%
Neutrogen	-	-	-	-
Activase/TNKase	8%	13%	8%	3%
Cymevene/Valcyte	8%	-26%	1%	60%
Viracept	-	-	-	-
Madopar	-	-	-	-
Lexotan	-	-	-	-
Inhibace/Inhibace Plus	-	-	-	-

¹ Roche Rx and Genentech Rx combined

7. Prescription medicines quarterly local sales growth Japan¹ in 2002 and 2003

	Q4 2002 vs. Q4 2001	Q1 2003 vs. Q1 2002	Q2 2003 vs. Q2 2002	Q3 2003 vs. Q3 2002
MabThera/Rituxan	12%	26%	24%	39%
NeoRecormon/Epogin	-	-	-	-
Rocephin	-7%	1%	25%	6%
Cellcept	19%	21%	19%	22%
Herceptin	125%	66%	58%	40%
Pegasys/Copegus	-	-	-	-
Xenical	-	-	-	-
Xeloda	-	-	-	-
Roaccutan/Accutane	-	-	-	-
Nutropin/Protropin	-	-	-	-
Kytril	4%	11%	13%	9%
Dilatrend	-	-	-	-
Pulmozyme	-	-	-	-
Neutrogen	-	-	-	-
Activase/TNKase	-	-	-	-
Cymevene/Valcyte	-	-	-	-
Viracept	4%	-6%	-7%	-1%
Madopar	1%	1%	-1%	-2%
Lexotan	23%	-8%	19%	-16%
Inhibace/Inhibace Plus	15%	2%	-5%	-63%

¹ Chugai is consolidated as from 1 October 2002

8. Prescription medicines quarterly local sales growth Europe/Rest of World in 2002 and 2003

	Q4 2002 vs. Q4 2001	Q1 2003 vs. Q1 2002	Q2 2003 vs. Q2 2002	Q3 2003 vs. Q3 2002
MabThera/Rituxan	65%	65%	54%	39%
NeoRecormon/Epogin	36%	40%	38%	33%
Rocephin	-9%	-10%	-17%	-6%
Cellcept	11%	28%	33%	29%
Herceptin	56%	56%	44%	32%
Pegasys/Copegus	397%	755%	453%	357%
Xenical	-14%	-17%	-14%	-6%
Xeloda	57%	49%	39%	36%
Roaccutan/Accutane	-20%	-26%	-31%	-13%
Nutropin/Protropin	21%	17%	12%	5%
Kytril	20%	10%	9%	13%
Dilatrend	17%	16%	22%	18%
Pulmozyme	-4%	1%	19%	13%
Neutrogen	-	-	-	-
Activase/TNKase	63%	-13%	30%	1%
Cymevene/Valcyte	26%	35%	1%	9%
Viracept	-38%	-18%	11%	-27%
Madopar	2%	6%	2%	7%
Lexotan	-5%	-11%	-12%	-2%
Inhibace/Inhibace Plus	-1%	8%	-13%	11%